DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Terpos E, Kastritis E, Roussou M. et al.
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis.
Leukemia 2008; 22 (12): 2247-2256
Search in:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.